

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the claims:

1. ~~(Canceled) A process for separating a VWF having a high activity from a VWF having a low activity, comprising the step of performing a chromatography using hydroxylapatite as a chromatography matrix.~~
2. ~~(Canceled) A process for the production of a composition having a high specific VWF activity comprising the step of purifying a VWF containing composition by means of hydroxylapatite chromatography.~~
3. ~~(Canceled) A process for raising the specific VWF activity of a VWF containing composition comprising the step of subjecting the VWF containing composition to a hydroxylapatite chromatography.~~
4. (Currently Amended) ~~The process according to claim 1, characterized in that~~ A process for separating a VWF having a high specific VWF activity from a VWF having a low specific VWF activity, said process comprising the steps: (a) binding VWF is bound to the a hydroxylapatite column matrix, (b) washing out VWF having a low-specific VWF activity is washed out less than 70 U per mg VWF antigen and then (c) eluting a VWF having a high specific VWF activity greater than 120 U per mg VWF antigen is eluted at a relatively high salt concentration.
5. (Currently Amended) The process according to claim [1] 4, characterized in that ~~the chromatography~~ the binding of step (a) is carried out at a pH between 5 and 7.

6. (Currently Amended) The process according to claim [1] 4, characterized in that a sodium or potassium phosphate containing solution is used as a running buffer.

7. (Currently Amended) The process according to claim [1] 4, ~~further comprising the use of wherein the washing of step (b) is performed using~~ a wash buffer containing 100 – 300 mM sodium or potassium phosphate, and the elution of step (c) is performed using an elution buffer containing 200 – 500 mM sodium or potassium phosphate.

8. (Currently Amended) The process according to claim [1] 4, ~~further comprising the steps of initially carrying out flow chromatography with hydroxylapatite, rechromatographing the flow fraction under binding conditions and eluting a highly pure VWF fraction wherein the VWF having a specific VWF activity greater than 120 U per mg VWF antigen eluted in step (c) is substantially free from fibrinogen and fibronectin.~~

9. (Currently Amended) The process according to claim [1] 4, characterized in that the hydroxylapatite column matrix is a ceramic hydroxylapatite.

10. (Original) The process according to claim 9, characterized in that the ceramic hydroxylapatite is type I or type II.

11. (Currently Amended) The process according to claim [1] 4, characterized in that a previously purified plasma fraction is used as a starting material.

12. (Currently Amended) The process according to claim [1] 4, characterized in that a further purified cryoprecipitate solution is used as a starting material.

13. (Currently Amended) The process according to claim [1] 4, characterized in that a cryoprecipitate solution precipitated with aluminum hydroxide is used as a starting material.

14. (Currently Amended) The process according to claim [1] 4, characterized in that a chromatographically pre-purified cryoprecipitate solution precipitated with aluminum hydroxide is used as a starting material.

15. (Currently Amended) The process according to claim [1] 4, further comprising the step of carrying out a pH precipitation prior to ~~the hydroxylapatite chromatography step (a)~~ to separate fibronectin.

16. (Currently Amended) The process according to claim [1] 4, characterized in that a protein solution with recombinantly produced VWF is used as a starting material.

17. (Currently Amended) The process according to claim [1] 4, characterized in that the hydroxylapatite column matrix ~~used~~ contains fluoride ions.

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled) ~~A VWF containing composition obtained by the process according to claim 1.~~

22. (Canceled) ~~A VWF containing composition having a specific activity of at least 120 U/mg protein.~~

23. (Canceled) ~~A composition according to claim 21, further wherein the composition has a specific VWF activity of at least 120 U/mg VWF antigen.~~

24. (Canceled) ~~A method of treating von Willebrand syndrome comprising the step of administering a composition according to claim 21 to a subject in need thereof.~~

25. (New) The process according to claim 4, wherein the washing of step (b) is performed at a salt concentration ranging from 100 – 300 mM and the elution of step (c) is performed at a salt concentration ranging from 200 – 500 mM.

26. (New) The process according to claim 4, wherein the washing of step (b) is performed at a salt concentration ranging from 200 – 300 mM and the elution of step (c) is performed at a salt concentration ranging from 250 – 500 mM.

27. (New) The process according to claim 4, wherein the washing of step (b) is performed at a salt concentration ranging from 200 – 270 mM and the elution of step (c) is performed at a salt concentration ranging from 300 – 400 mM.